Semaglutide significantly reduces cardiovascular events and adverse effects in overweight and obese patients. The study highlights semaglutide’s superiority over other GLP-1 agonists for cardiovascular health.
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2024 Diabetes Prevention Awareness Center.